STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 195[illegible]

TO: Nancy Zhang **Location: REM-3D30&3C70** **Art Unit: 1614** **Thursday, July 27, 2006** **Case Serial Number: 10/501069**	**From: Mary Jane Ruhl** **Location: Biotech-Chem Library** **Remsen 1-A-62** **Phone: 571-272-2524** **maryjane.ruhl@uspto.gov**

Search Notes

Examiner Zhang,

Here are the results for your recent search request.

Please feel free to contact me if you have any questions about these results.

Thank you for using STIC services. We appreciate the opportunity to serve you.

Sincerely,

Mary Jane Ruhl
Technical Information Specialist
STIC
Remsen 1-A-62
Ext. 22524

structure search

ACCESS DB # 195821

FOR OFFICIAL USE ONLY *PLEASE PRINT CLEARLY*

196750

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Nancy Zhang Examiner # : 82360 Date: 7/18/2006

Art Unit: 1614 Phone Number: 2-8270 Serial Number: 10/501,069

Location (Bldg/Room#): REM 3D30 (Mailbox #): REM 3C70 Results Format Preferred (circle): (PAPER) DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: See attached Bib Sheet

Inventors (please provide full names):

Earliest Priority Date: 12/16/2002

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only ***Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.***

Please search for compositions containing both of the following two compounds:

(1) pioglitazone 118384-10-4 and (2) 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid 203855-58-7

with respect to the administering of the composition.

<If nothing is found, please consider another compound from claim (7) for the first compound.

OR

another compound from Claim (9) for the second compound.>

<One page of claim sheet is attached>

Thank you very much!

the formula (I) ranges from 10^{-3} to 40, preferably from 10^{-3} to 10 and better still from 10^{-3} to 1.

7. Pharmaceutical composition according to any one of the preceding claims, characterised in that the glitazone is chosen from rosiglitazone, pioglitazone, isaglitazone, KRP 297, CS 011, T 174, NP 0110, englitazone, darglitazone and ciglitazone.

8. Pharmaceutical composition according to the preceding claim, characterised in that the glitazone is chosen from rosiglitazone, pioglitazone, isaglitazone and KRP 297.

9. Composition according to any one of the preceding claims, characterised in that the compound of the formula (I) is chosen from:

- 2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid
- 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid
- 2-cyclohexylmethyl-4-(4-methoxyphenyl)-4-oxobutanoic acid
- 2-benzyl-4-phenyl-4-oxobutanoic acid
- 2-(β-naphthylmethyl)-4-phenyl-4-oxobutanoic acid
- 2-benzyl-4-(β-naphthyl)-4-oxobutanoic acid
- 2-[(4-chlorophenyl)methyl]-4-(4-methoxyphenyl)-4-oxobutanoic acid
- 2-benzyl-4-(4-methylphenyl)-4-oxobutanoic acid
- 4-(4-fluorophenyl)-2-[(4-methoxyphenyl)methyl]-4-oxobutanoic acid
- 2-benzyl-4-(3,4-methylenedioxyphenyl)-4-oxobutanoic acid
- 2-benzyl-4-cyclohexyl-4-oxobutanoic acid
- 4-phenyl-2-[(tetrahydrofur-2-yl)methyl]-4-oxobutanoic acid,

the solvates, enantiomers and salts of these acids.

10. Composition according to Claim 9, characterised in that the compound of the formula (I) is chosen from:

- (-)-2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid
- (+)-2-benzyl-4-(4-methoxyphenyl)-4-oxobutanoic acid
- (-)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid
- (+)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid.

=> d ibib abs ind hitstr 16 1-1

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:551378 HCAPLUS
DOCUMENT NUMBER: 139:106488
TITLE: Pharmaceutical composition comprising a **glitazone** and a 4-oxobutanoic acid for treating diabetes
INVENTOR(S): **Moinet, Gerard; Marais, Dominique**
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003057216	A1	20030717	WO 2002-EP14311	20021216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2834640	A1	20030718	FR 2002-335	20020111
FR 2834640	B1	20040924		
CA 2473043	AA	20030717	CA 2002-2473043	20021216
AU 2002361421	A1	20030724	AU 2002-361421	20021216
EP 1463503	A1	20041006	EP 2002-796640	20021216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015498	A	20041228	BR 2002-15498	20021216
CN 1599608	A	20050323	CN 2002-824406	20021216
US 2005085489	A1	20050421	US 2003-501069	20021216
JP 2005516963	T2	20050609	JP 2003-557574	20021216
ZA 2004006329	A	20050920	ZA 2004-6329	20040810
PRIORITY APPLN. INFO.:			FR 2002-335 A	20020111
			WO 2002-EP14311 W	20021216

OTHER SOURCE(S): MARPAT 139:106488

AB The present invention relates to a pharmaceutical composition suitable for oral administration comprising, as active principles, a **glitazone** and a 4-oxobutanoic acid (weight ratio of 10-3-10), in combination with one or more pharmaceutically acceptable excipients. These compns. are particularly suitable for treating non-insulin-dependent diabetes and pathologies associated with insulin resistance syndrome. For example, a tablet contained (+)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid (Compound P) 50 mg, **rosiglitazone** 4 mg, microcryst. cellulose 17 mg, lactose 26 mg, hydroxypropyl cellulose 11 mg, croscarmellose sodium 15 mg, colloidal silica 2 mg, and magnesium stearate 2 mg.

IC ICM A61K031-425
ICS A61K031-44; A61P003-10
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
ST **glitazone** oxobutanoate oral antidiabetic

IT Nerve, disease
(neuropathy; oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes and complications)
IT Diabetes mellitus
(non-insulin-dependent; oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes)
IT Atherosclerosis
Hypertension
Kidney, disease
Obesity
(oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes and complications)
IT Dyslipidemia
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes and complications)
IT Antidiabetic agents
Drug delivery systems
(oral; oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes)
IT Eye, disease
(retinopathy; oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes and complications)
IT Drug delivery systems
(tablets; oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes)
IT **68973-52-4 68973-53-5 74772-77-3,**
Ciglitazone 89496-35-5 104905-00-2
109229-58-5, Englitazone 111025-46-8,
Pioglitazone 118384-10-4, T 174 (Pharmaceutical)
122320-73-4, Rosiglitazone 125190-43-4
141200-24-0, Darglitazone 161600-01-7,
Isaglitazone 179068-71-4 203855-56-5
203855-57-6 203855-58-7 203855-59-8
203855-60-1 203855-61-2 203855-62-3
203855-63-4 203855-65-6 203855-66-7
213252-19-8, KRP 297 **560131-16-0**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes)
IT **9004-10-8,** Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes)
IT **68973-52-4 68973-53-5 74772-77-3,**
Ciglitazone 89496-35-5 104905-00-2
109229-58-5, Englitazone 111025-46-8,
Pioglitazone 118384-10-4, T 174 (Pharmaceutical)
122320-73-4, Rosiglitazone 125190-43-4
141200-24-0, Darglitazone 161600-01-7,
Isaglitazone 179068-71-4 203855-56-5
203855-57-6 203855-58-7 203855-59-8
203855-60-1 203855-61-2 203855-62-3
203855-63-4 203855-65-6 203855-66-7
213252-19-8, KRP 297 **560131-16-0**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes)
RN 68973-52-4 HCAPLUS
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-,

(αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

(1)



RN 68973-53-5 HCAPLUS
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

(1)



RN 74772-77-3 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(1-methylcyclohexyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 89496-35-5 HCAPLUS
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 104905-00-2 HCAPLUS
CN Benzenebutanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



(4)

RN 109229-58-5 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[3,4-dihydro-2-(phenylmethyl)-2H-1-benzopyran-6-yl]methyl]- (9CI) (CA INDEX NAME)



RN 111025-46-8 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 118384-10-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[2-(2-naphthalenylmethyl)-5-benzoxazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 122320-73-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 125190-43-4 HCAPLUS
CN Benzenepropanoic acid, α-(2-cyclohexyl-2-oxoethyl)- (9CI) (CA INDEX NAME)



RN 141200-24-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 161600-01-7 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]- (9CI) (CA INDEX NAME)



RN 179068-71-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[7-[[4-(trifluoromethyl)phenyl]methoxy]-3-quinolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 203855-56-5 HCAPLUS
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-57-6 HCAPLUS
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 203855-58-7 HCAPLUS
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 203855-59-8 HCAPLUS
CN 2-Naphthalenepropanoic acid, α-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 203855-60-1 HCAPLUS
CN 2-Naphthalenebutanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-61-2 HCAPLUS
CN Benzenebutanoic acid, α-[(4-chlorophenyl)methyl]-4-methoxy-γ-oxo- (9CI) (CA INDEX NAME)



(7)

RN 203855-62-3 HCAPLUS
CN Benzenebutanoic acid, α-(cyclohexylmethyl)-4-methoxy-γ-oxo- (9CI) (CA INDEX NAME)



(3)

RN 203855-63-4 HCAPLUS
CN Benzenebutanoic acid, 4-methyl-γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



(8)

RN 203855-65-6 HCAPLUS
CN 1,3-Benzodioxole-5-butanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



(10)

RN 203855-66-7 HCAPLUS
CN 2-Furanpropanoic acid, tetrahydro-α-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



(12)

RN 213252-19-8 HCAPLUS
CN Benzamide, 5-[(2,4-dioxo-5-thiazolidinyl)methyl]-2-methoxy-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 560131-16-0 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[(5-methoxy-1H-benzimidazol-2-yl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT **9004-10-8**, Insulin, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(resistance; oral compns. comprising **glitazone** and 4-oxobutanoic acid derivative for treatment of diabetes)
RN 9004-10-8 HCAPLUS
CN Insulin (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Requested compds. Plz. see Inventor Search & Claim 9 where compds & structures are keyed together

=> d l19 1-13

L19 ANSWER 1 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **203855-66-7** REGISTRY
ED Entered STN: 09 Apr 1998
CN 2-Furanpropanoic acid, tetrahydro-α-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H18 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 09 Apr 1998

L19 ANSWER 2 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **203855-65-6** REGISTRY
ED Entered STN: 09 Apr 1998
CN 1,3-Benzodioxole-5-butanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H16 O5
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 09 Apr 1998

L19 ANSWER 3 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **203855-63-4** REGISTRY
ED Entered STN: 09 Apr 1998
CN Benzenebutanoic acid, 4-methyl-γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)

FS 3D CONCORD
MF C18 H18 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 09 Apr 1998

L19 ANSWER 4 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **203855-62-3** REGISTRY
ED Entered STN: 09 Apr 1998
CN Benzenebutanoic acid, α-(cyclohexylmethyl)-4-methoxy-γ-oxo- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H24 O4
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 09 Apr 1998

L19 ANSWER 5 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **203855-60-1** REGISTRY
ED Entered STN: 09 Apr 1998
CN 2-Naphthalenebutanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H18 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ED Entered STN: 09 Apr 1998

L19 ANSWER 6 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **203855-59-8** REGISTRY
ED Entered STN: 09 Apr 1998
CN 2-Naphthalenepropanoic acid, α-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C21 H18 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ED Entered STN: 09 Apr 1998

L19 ANSWER 7 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **203855-58-7** REGISTRY
ED Entered STN: 09 Apr 1998
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H15 F O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 09 Apr 1998

L19 ANSWER 8 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **203855-57-6** REGISTRY
ED Entered STN: 09 Apr 1998
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C17 H15 F O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 09 Apr 1998

L19 ANSWER 9 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **203855-56-5** REGISTRY
ED Entered STN: 09 Apr 1998
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C17 H15 F O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

6 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
6 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 09 Apr 1998

L19 ANSWER 10 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **125190-43-4** REGISTRY
ED Entered STN: 02 Feb 1990
CN Benzenepropanoic acid, α-(2-cyclohexyl-2-oxoethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
DR 125470-14-6
MF C17 H22 O3
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

8 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
8 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 02 Feb 1990

L19 ANSWER 11 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **104905-00-2** REGISTRY
ED Entered STN: 25 Oct 1986
CN Benzenebutanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)
FS 3D CONCORD
DR 124640-79-5
MF C17 H16 O3
SR CA
LC STN Files: BEILSTEIN*, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

10 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 25 Oct 1986

L19 ANSWER 12 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **68973-53-5** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-, (S)-
OTHER NAMES:
CN (S)-(+)-3-p-Methoxybenzoyl-2-benzylpropionic acid
FS STEREOSEARCH
MF C18 H18 O4
LC STN Files: BEILSTEIN*, CA, CAPLUS, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

7 REFERENCES IN FILE CA (1907 TO DATE)
7 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 16 Nov 1984

L19 ANSWER 13 OF 13 REGISTRY COPYRIGHT 2006 ACS on STN
RN **68973-52-4** REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-, (R)-
OTHER NAMES:
CN (-)-2-Benzyl-3-p-methoxybenzoylpropionate
CN (R)-(-)-3-p-Methoxybenzoyl-2-benzylpropionic acid
FS STEREOSEARCH
MF C18 H18 O4
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, MEDLINE, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

12 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
12 REFERENCES IN FILE CAPLUS (1907 TO DATE)
ED Entered STN: 16 Nov 1984

=> d 125
L25 HAS NO ANSWERS
L25 STR



This compd. could not be located in Inventor Search, so I drew the structure - 0 compounds in Registry.

* 9th on the Claim 9 list

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

```
=> d que stat l21
L8          1 SEA FILE=REGISTRY ABB=ON  118384-10-4/RN
L17        12 SEA FILE=REGISTRY ABB=ON  (68973-52-4 OR 68973-53-5 OR
              203855-58-7 OR 203855-57-6 OR 203855-36-5 OR 203855-62-3 OR
              104905-00-2 OR 203855-59-8 OR 203855-60-1 OR 203855-63-4 OR
              203855-65-6 OR 125190-43-4 OR 203855-66-7)/RN
L18         1 SEA FILE=REGISTRY ABB=ON  203855-56-5/RN
L19        13 SEA FILE=REGISTRY ABB=ON  L17 OR L18
L20        20 SEA FILE=HCAPLUS ABB=ON  L19
L21         1 SEA FILE=HCAPLUS ABB=ON  L20 AND (L8 OR ?PIOGLITAZONE?)

=> d ibib abs hitstr l21 1-1

L21  ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2003:551378  HCAPLUS
DOCUMENT NUMBER:          139:106488
TITLE:                    Pharmaceutical composition comprising a glitazone and
                          a 4-oxobutanoic acid for treating diabetes
INVENTOR(S):              Moinet, Gerard; Marais, Dominique
PATENT ASSIGNEE(S):       Merck Patent Gmbh, Germany
SOURCE:                   PCT Int. Appl., 24 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2003057216         A1    20030717    WO 2002-EP14311          20021216
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
             UG, US, UZ, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     FR 2834640            A1    20030718    FR 2002-335              20020111
     FR 2834640            B1    20040924
     CA 2473043            AA    20030717    CA 2002-2473043          20021216
     AU 2002361421         A1    20030724    AU 2002-361421           20021216
     EP 1463503            A1    20041006    EP 2002-796640           20021216
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
     BR 2002015498         A     20041228    BR 2002-15498            20021216
     CN 1599608            A     20050323    CN 2002-824406           20021216
     US 2005085489         A1    20050421    US 2003-501069           20021216
     JP 2005516963         T2    20050609    JP 2003-557574           20021216
     ZA 2004006329         A     20050920    ZA 2004-6329             20040810
PRIORITY APPLN. INFO.:                       FR 2002-335          A   20020111
                                             WO 2002-EP14311      W   20021216

OTHER SOURCE(S):          MARPAT 139:106488
AB   The present invention relates to a pharmaceutical composition suitable for oral
     administration comprising, as active principles, a glitazone and a
     4-oxobutanoic acid (weight ratio of 10-3-10), in combination with one or more
     pharmaceutically acceptable excipients.  These compns. are particularly
     suitable for treating non-insulin-dependent diabetes and pathologies
```

associated with insulin resistance syndrome. For example, a tablet contained (+)-2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid (Compound P) 50 mg, rosiglitazone 4 mg, microcryst. cellulose 17 mg, lactose 26 mg, hydroxypropyl cellulose 11 mg, croscarmellose sodium 15 mg, colloidal silica 2 mg, and magnesium stearate 2 mg.

IT **68973-52-4 68973-53-5 104905-00-2**
118384-10-4, T 174 (Pharmaceutical) **125190-43-4**
203855-56-5 203855-57-6 203855-58-7
203855-59-8 203855-60-1 203855-62-3
203855-63-4 203855-65-6 203855-66-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral compns. comprising glitazone and 4-oxobutanoic acid derivative for treatment of diabetes)

RN 68973-52-4 HCAPLUS
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 68973-53-5 HCAPLUS
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 104905-00-2 HCAPLUS
CN Benzenebutanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 118384-10-4 HCAPLUS
CN 2,4-Thiazolidinedione, 5-[[2-(2-naphthalenylmethyl)-5-benzoxazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 125190-43-4 HCAPLUS
CN Benzenepropanoic acid, α-(2-cyclohexyl-2-oxoethyl)- (9CI) (CA INDEX NAME)



RN 203855-56-5 HCAPLUS
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-57-6 HCAPLUS
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 203855-58-7 HCAPLUS
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 203855-59-8 HCAPLUS
CN 2-Naphthalenepropanoic acid, α-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 203855-60-1 HCAPLUS
CN 2-Naphthalenebutanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-62-3 HCAPLUS
CN Benzenebutanoic acid, α-(cyclohexylmethyl)-4-methoxy-γ-oxo- (9CI) (CA INDEX NAME)



RN 203855-63-4 HCAPLUS
CN Benzenebutanoic acid, 4-methyl-γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-65-6 HCAPLUS
CN 1,3-Benzodioxole-5-butanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-66-7 HCAPLUS
CN 2-Furanpropanoic acid, tetrahydro-α-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d que stat l28
L8          1 SEA FILE=REGISTRY ABB=ON  118384-10-4/RN
L17        12 SEA FILE=REGISTRY ABB=ON  (68973-52-4 OR 68973-53-5 OR
              203855-58-7 OR 203855-57-6 OR 203855-36-5 OR 203855-62-3 OR
              104905-00-2 OR 203855-59-8 OR 203855-60-1 OR 203855-63-4 OR
              203855-65-6 OR 125190-43-4 OR 203855-66-7)/RN
L18         1 SEA FILE=REGISTRY ABB=ON  203855-56-5/RN
L19        13 SEA FILE=REGISTRY ABB=ON  L17 OR L18
L20        20 SEA FILE=HCAPLUS ABB=ON  L19
L28         1 SEA FILE=USPATFULL ABB=ON  L20 AND (L8 OR ?PIOGLITAZONE?)

=> d ibib abs hitstr l28 1-1

L28  ANSWER 1 OF 1  USPATFULL on STN
ACCESSION NUMBER:        2005:99570  USPATFULL
TITLE:                   Pharmaceutical composition comprising a glitazone and a
                         4-oxobutanoic acid, and the use thereof for treating
                         diabetes
INVENTOR(S):             Moinet, Gerard, Orsay, FRANCE

                              NUMBER        KIND    DATE
                         ---------------- ------ --------
PATENT INFORMATION:      US 2005085489      A1   20050421
APPLICATION INFO.:       US 2003-501069     A1   20021216  (10)
                         WO 2002-EP14311         20021216

                               NUMBER         DATE
                         ------------------ --------
PRIORITY INFORMATION:    FR 2002-335        20020111
DOCUMENT TYPE:           Utility
FILE SEGMENT:            APPLICATION
LEGAL REPRESENTATIVE:    MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON
                         BLVD., SUITE 1400, ARLINGTON, VA, 22201, US
NUMBER OF CLAIMS:        19
EXEMPLARY CLAIM:         1
LINE COUNT:              477
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The present invention relates to a pharmaceutical composition
       comprising, as active principles, a 4-oxobutanoic acid and a glitazone,
       in combination with one or more pharmaceutically acceptable excipients.
       These compositions are particularly suitable for treating diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT   68973-52-4 68973-53-5 104905-00-2
       118384-10-4, T 174 (Pharmaceutical) 125190-43-4
       203855-56-5 203855-57-6 203855-58-7
       203855-59-8 203855-60-1 203855-62-3
       203855-63-4 203855-65-6 203855-66-7
         (oral compns. comprising glitazone and 4-oxobutanoic acid derivative for
         treatment of diabetes)
RN   68973-52-4  USPATFULL
CN   Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-,
       (αR)- (9CI)  (CA INDEX NAME)

       Absolute stereochemistry.  Rotation (-).
```



RN 68973-53-5 USPATFULL
CN Benzenebutanoic acid, 4-methoxy-γ-oxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 104905-00-2 USPATFULL
CN Benzenebutanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 118384-10-4 USPATFULL
CN 2,4-Thiazolidinedione, 5-[[2-(2-naphthalenylmethyl)-5-benzoxazolyl]methyl]- (9CI) (CA INDEX NAME)



RN 125190-43-4 USPATFULL
CN Benzenepropanoic acid, α-(2-cyclohexyl-2-oxoethyl)- (9CI) (CA INDEX NAME)



RN 203855-56-5 USPATFULL
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-57-6 USPATFULL
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 203855-58-7 USPATFULL
CN Benzenebutanoic acid, 4-fluoro-γ-oxo-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 203855-59-8 USPATFULL
CN 2-Naphthalenepropanoic acid, α-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 203855-60-1 USPATFULL
CN 2-Naphthalenebutanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-62-3 USPATFULL
CN Benzenebutanoic acid, α-(cyclohexylmethyl)-4-methoxy-γ-oxo- (9CI) (CA INDEX NAME)



RN 203855-63-4 USPATFULL
CN Benzenebutanoic acid, 4-methyl-γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-65-6 USPATFULL
CN 1,3-Benzodioxole-5-butanoic acid, γ-oxo-α-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 203855-66-7 USPATFULL
CN 2-Furanpropanoic acid, tetrahydro-α-(2-oxo-2-phenylethyl)- (9CI) (CA INDEX NAME)



```
=> d his ful

     (FILE 'HOME' ENTERED AT 14:17:16 ON 27 JUL 2006)

     FILE 'HCAPLUS' ENTERED AT 14:17:25 ON 27 JUL 2006
                  E MOINET GERARD/AU
L1             66 SEA ABB=ON  ("MOINET GERARD"/AU OR "MOINET GERARD G"/AU OR
                  "MOINET GERARD H"/AU)
                  E MARAIS DOMINIQUE/AU
L2             12 SEA ABB=ON  "MARAIS DOMINIQUE"/AU
L3              8 SEA ABB=ON  L1 AND L2
L4              1 SEA ABB=ON  L3 AND ?GLITAZONE?
                  SELECT RH L4 1-1 RN

     FILE 'REGISTRY' ENTERED AT 14:18:40 ON 27 JUL 2006
L5             26 SEA ABB=ON  (104905-00-2/BI OR 109229-58-5/BI OR 111025-46-8/BI
                   OR 118384-10-4/BI OR 122320-73-4/BI OR 125190-43-4/BI OR
                  141200-24-0/BI OR 161600-01-7/BI OR 179068-71-4/BI OR 203855-56
                  -5/BI OR 203855-57-6/BI OR 203855-58-7/BI OR 203855-59-8/BI OR
                  203855-60-1/BI OR 203855-61-2/BI OR 203855-62-3/BI OR 203855-63
                  -4/BI OR 203855-65-6/BI OR 203855-66-7/BI OR 213252-19-8/BI OR
                  560131-16-0/BI OR 68973-52-4/BI OR 68973-53-5/BI OR 74772-77-3/
                  BI OR 89496-35-5/BI OR 9004-10-8/BI)

     FILE 'HCAPLUS' ENTERED AT 14:27:51 ON 27 JUL 2006
L6              1 SEA ABB=ON  L4 AND L5
L7                ANALYZE L6 1-1 CT :      10 TERMS

     FILE 'REGISTRY' ENTERED AT 14:41:57 ON 27 JUL 2006
L8              1 SEA ABB=ON  118384-10-4/RN
L9              1 SEA ABB=ON  203855-58-7/RN

     FILE 'HCAPLUS' ENTERED AT 14:42:17 ON 27 JUL 2006
L10             1 SEA ABB=ON  (L8 OR ?PIOGLITAZONE?) AND L9

     FILE 'REGISTRY' ENTERED AT 14:45:06 ON 27 JUL 2006
L11             2 SEA ABB=ON  (68973-52-4 OR 68973-53-5)/RN

     FILE 'HCAPLUS' ENTERED AT 14:45:27 ON 27 JUL 2006
L12             1 SEA ABB=ON  (L8 OR ?PIOGLITAZONE?) AND L11

     FILE 'REGISTRY' ENTERED AT 15:18:44 ON 27 JUL 2006
L13             0 SEA ABB=ON  (68973-52-4, 68973-53-5, 203855-58-7, 203855-57-6,
                  203855-36-5, 203855-62-3, 104905-00-2, 203855-59-8, 203855-60-1
                  , 203855-63-4, 203855-65-6, 125190-43-4, 203855-66-7)/RN
L14             0 SEA ABB=ON  (68973-52-4, 68973-53-5, 203855-58-7, 203855-57-6,
                  203855-36-5, 203855-62-3, 104905-00-2, 203855-59-8, 203855-60-1
                  , 203855-63-4)/RN
L15             0 SEA ABB=ON  (68973-52-4, 68973-53-5, 203855-58-7, 203855-57-6,
                  203855-36-5, 203855-62-3, 104905-00-2)/RN
L16             0 SEA ABB=ON  (68973-52-4, 68973-53-5, 203855-58-7, 203855-57-6)/
                  RN

     FILE 'REGISTRY' ENTERED AT 15:21:38 ON 27 JUL 2006
L17            12 SEA ABB=ON  (68973-52-4 OR 68973-53-5 OR 203855-58-7 OR
                  203855-57-6 OR 203855-36-5 OR 203855-62-3 OR 104905-00-2 OR
                  203855-59-8 OR 203855-60-1 OR 203855-63-4 OR 203855-65-6 OR
                  125190-43-4 OR 203855-66-7)/RN
L18             1 SEA ABB=ON  203855-56-5/RN
```

L19 13 SEA ABB=ON L17 OR L18

FILE 'HCAPLUS' ENTERED AT 15:24:10 ON 27 JUL 2006
L20 20 SEA ABB=ON L19
L21 1 SEA ABB=ON L20 AND (L8 OR ?PIOGLITAZONE?) / cit from CAPlus

FILE 'REGISTRY' ENTERED AT 15:24:45 ON 27 JUL 2006
L22 STR
L23 0 SEA SSS SAM L22
L24 0 SEA SSS FUL L22
L25 STR L22
L26 0 SEA SSS SAM L25
L27 0 SEA SSS FUL L25 0 compds. for structure (9th compd. in claim 9)

FILE 'USPATFULL' ENTERED AT 15:30:42 ON 27 JUL 2006
L28 1 SEA ABB=ON L20 AND (L8 OR ?PIOGLITAZONE?) / cit from USPatFull

FILE HOME 0 cits from Medline, Embase, Biosis, Japio, Jicst

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Jul 2006 VOL 145 ISS 5
FILE LAST UPDATED: 26 Jul 2006 (20060726/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2006 HIGHEST RN 896142-63-5
DICTIONARY FILE UPDATES: 25 JUL 2006 HIGHEST RN 896142-63-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 27 Jul 2006 (20060727/PD)
FILE LAST UPDATED: 27 Jul 2006 (20060727/ED)
HIGHEST GRANTED PATENT NUMBER: US7082615
HIGHEST APPLICATION PUBLICATION NUMBER: US2006168703
CA INDEXING IS CURRENT THROUGH 27 Jul 2006 (20060727/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 27 Jul 2006 (20060727/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2006